Kornimate/medical-research-clean huggingface dataset:
administration of vaginal and rectal progesterone during fet cycles

Conditions: Infertility

Summary: observational study of reproductive outcome after frozen embryo transfer in hrt with vaginal and rectal progesterone.

cohort of patients treated with autologous blastocyst at the fertility clinic skive regional hospital in hrt cycle. estradiol stimulation started on second cycle day and on day 12 - 20 vaginal and rectal progesterone is added. blastocyst transfer on 6th progesterone treatment day. serum progesterone and hcg measurement 9 or 11 days after embryo transfer.

Eligibility criteria:
inclusion criteria: * frozen embryo transfer cycles in hrt cycles exclusion criteria: * donor frozen embryo transfer

Keywords: progesterone hrt frozen embryo transfer
dog presence and oxytocin on trust towards therapists

Conditions: Depressive Symptoms; Human-Animal Interaction

Summary: oxytocin has been proposed as a neuroendocrine mechanism that may mediate the relationship between dog ownership and positive health outcomes and be linked to human-dog interactions and is thought to be a mechanism of interspecies bonding. while the role of oxytocin in human bonding behaviours and social behaviour, in general, is becoming well-established the role of oxytocin in human-animal interaction and animal-assisted interventions (aai) remains unclear. this research gap calls for more high-quality research investigating this possible neuroendocrine underlying mechanism to advance knowledge about aai. if oxytocin indeed might be involved in interspecies bonding, intranasally administered oxytocin should not only enhance trust toward a human but also towards a dog.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * signed informed consent exclusion criteria: * pregnancy * being scared of dogs or dog hair allergy by self-report * any acute or chronic disease (e.g., chronic pain, hypertension, heart disease, renal disease, liver disease, diabetes, respiratory disease, skin pathologies etc.) * current medications (psychoactive medication, narcotics, intake of analgesics) or being currently in psychological or psychiatric treatment * drug consumption (thc, cocaine, heroin, etc.) within the past 24h before study appointment * ongoing psychotherapy treatment * sexual intercourse within the past 24h before study appointment * current disease involving respiratory system (e.g., influence, asthma etc.) * insufficient german language skills to understand the instructions

Keywords: depressive symptoms human-animal interaction animal-assisted interventions trust
the efficacy of kinesio taping on lymphedema following head and neck cancer therapy

Conditions: Lymphedema; Head and Neck Cancer; Kinesio Taping; Therapy

Summary: purpose off the study is investigating to efficacy of kinesio taping on neck lymphedema after the head and neck cancer therapy.

the neck lymphedema is a multidirectional process that depends on lymphatic circulation issues. the lymphedema can be treated using such as therapies, drugs or surgeries. there are few techniques for treatment of neck lymphedema and also in our best knowledge the kinesio taping therapy on lymphedema following neck cancer therapy had not been investigated or published. the study will assess the efficacy of kinesio taping in neck lymphedema with manual therapy after the head and neck cancer treatment.

Eligibility criteria:
inclusion criteria: * age between 18-70 years * external neck lymphedema * head and neck cancer treatment patients * patients who have not open wound on neck * patients who were accept to consent form exclusion criteria: * mental disorders cognitive limitations pregnancy out of age 18-70 years old patients who were not accept to consent form

Keywords: kinesio taping neck lymphedema head cancer therapy
early exposure to lead and adult antisocial outcomes

Conditions: Lead Poisoning

Summary: prior research indicates a link between early lead exposure and risk for delinquent behavior. in this study, we follow a large birth cohort from the cincinnati lead study into early adulthood to determine whether this increased risk persists. outcome measures include official arrest records, diagnoses of substance abuse disorder and antisocial personality disorder, self-report of delinquent behavior, and a psychopathy scale. predictors include pre-natal and post-natal blood lead levels. multivariate statistical methods will control for potential confounders/covariates.


Eligibility criteria:
inclusion criteria: (1) part of original cls birth cohort - exclusion criteria: (1) moved out of geographic area -
quality of life and neurodevelopment assessment of children with congenital heart disease aged 2 to 4 years

Conditions: Congenital Heart Disease

Summary: congenital heart diseases (chd) are the firt cause of congenital malformations (8 for 1000 births). since the 90's, great advances in prenatal diagnosis, pediatric cardiac surgery, intensive care, and cardiac catheterization have reduced morbidity and early mortality in this population. nowadays, health-related quality of life (hrqol) assessment of this population is in the foreground. our team is a tertiary care center for management of patients with chd, from the fetal period to adulthood. the investigators have been conducting a clinical research program on hrqol in pediatric and chd. the investigators thus demonstrated the link between cardiopulmonary fitness and hrqol in children with chd aged 8 to 18 years, the correlation between functional class and hrqol in adults with chd, the impact of therapeutic education on hrqol in children under anticoagulants and the lack of difference between the hrqol of children chd aged 5 to 7 years old and that of control children. currently, no controlled cross-sectional quality of life study assessment has been leded in the youngest children with chd. this present study therefore extends our work in younger children aged 2 to 4 years.

248 patients will be enrolled in this study (124 children in each group). patients from group 1 will be included during their annual medical check-up. hrqol questionnaire, neurodevelopmental status scale and clinical status will be assessed during this site visit. no supplementary visit, directly related to the research, will be necessary. three sites will participate to the study, members of he french national network for complex congenital heart diseases (m3c) . participants (healthy children) from group 2 will be included from kindergartens and schools. the prior agreement of the ministry of national education will be obtained before any procedure related to this study.

Eligibility criteria:
inclusion criteria: * children aged 2 to 4 years old. * group 2 : chldren with chd (as defined in the acc-chd classification). exclusion criteria: * other comorbidity affecting quality of life (polymalformative syndrome, extracardiac organ failure, severe genetic disease). * surgical procedure during the last 6 months. * inability to understand the hrqol questionnaire (parents) :non-french speaker, severe intellectual disability.

Keywords: health related quality of life pediatrics cardiology
use of the cannabinoid nabilone for the promotion of sleep in chronic, non-malignant pain patients

Conditions: Pain; Insomnia

Summary: sleep disturbance is perhaps one of the most prevalent complaints of patients with long-standing painful conditions. nabilone is a medication that is approved by health canada as an anti-emetic (prevent vomiting) for patients undergoing chemotherapy. nabilone, due to its sleep promoting properties, is sometimes prescribed by physicians to pain patients to help improve their sleep. however, there is no direct research evidence to either support or refute this practice. this study will investigate if nabilone is effective in improving sleep in insomnia and pain patients.

rationale: the current evidence suggests a sleep promoting effect of thc. although, there is some support from pre-clinical and small sample size human studies suggesting a direct sleep enhancing effect, it remains unclear from the larger clinical trials, whether improved sleep is an epiphenomena secondary to improvements in the primary outcome measures ( i.e., pain, nausea or spasticity). there are no studies evaluating the sleep promoting effects of thc or analogues in patients with primary insomnia or objectively evaluating sleep at baseline and following treatment with thc or analogues in patients suffering from chronic pain disorder and insomnia. cannabinoids have the potential of simultaneously improving sleep and lessening chronic, non-malignant pain, thereby interrupting the vicious cycle of pain and sleep disturbance. an investigation of the efficacy of cannabinoids in treating insomnia in chronic, non-malignant pain patients is therefore warranted. research question: to evaluate if nabilone (cesamet) is effective in improving sleep in patients with insomnia and chronic, non-malignant pain

Eligibility criteria:
inclusion criteria * history of insomnia and chronic, non-malignant pain. * patient not currently being prescribed opiates for pain management * subject has no known clinically significant abnormal vital signs or other significant clinical findings at screening. exclusion criteria * patients with a history of sensitivity of cannabinoids. * patients currently taking hypnotics, psychotomimetic substances, cns depressants or tricyclic antidepressants that may increase the cns-depressant effects of nabilone. * patients with active cardiac disease or respiratory disorders. * patients with a history of psychotic reactions, schizophrenia, bipolar disorder or any serious untreated mental disorder. * presence of untreated sleep disorder (other than insomnia) as detected using the screening overnight psg. * alcohol or substance abuse (according to dsm-iv) during the last 6 months prior to baseline. * patients with liver disease that may interfere with the clearance of nabilone. * patients who are nursing, pregnant or likely to become pregnant throughout the course of the study. during the study, female patients will be asked to use an effective method of birth control.

Keywords: pain insomnia nabilone
silent cerebrovascular lesion and cognitive decline prevention by cholesterol lowering in elderly af patients

Conditions: Atrial Fibrillation; Neuropsychology; Magnetic Resonance Imaging; Inflammation; Hemostasis

Summary: in elderly patients with atrial fibrillation (af) the presence of silent brain infarcts and neurocognitive deficit is high despite adequate treatment with oral anticoagulation. atherosclerosis is considered to be a chronic inflammatory disease and thrombosis and inflammation are strongly correlated. atrial fibrillation is linked with increased levels of inflammatory markers and intensive cholesterol lowering has proven to reduce inflammation. in a prospective double-blind randomized pilot-study we want to test the hypothesis, that addition of intensive cholesterol lowering treatment besides adequate oral anticoagulation will reduce cerebrovascular lesions and will be beneficial for neurocognitive status in elderly af patients.


Eligibility criteria:
inclusion criteria: * elderly patients (\>68 and \<82 years) with atrial fibrillation and adequate oral anticoagulation therapy and cholesterol levels between 4,5 mmol/l and 7 mmol/l exclusion criteria: * indication for cholesterol lowering treatment according to dutch cbo-cholesterol guidelines (2004)

Keywords: atrial fibrillation elderly cholesterol lowering neurocognitive function cerebrovascular lesion
eletriptan provides consistent migraine relief: results of a within-patient multiple-dose study

Conditions: Migraine Without Aura; Migraine With Aura

Summary: evaluation of headache response at 2 hours for active treated attacks for increasing dose.


Eligibility criteria:
inclusion criteria: * male and female subjects in good general health, aged 18 to 65 years. * subjects should meet ihs diagnostic criteria for migraine with or without aura. * based on past history, subjects should expect to suffer at least one acute attack of migraine with or without aura, each 6 weeks exclusion criteria: * known coronary-artery disease, clinically significant arrhythmia, heart failure, or uncontrolled hypertension. * pregnant or lactating women. * clinically significant electrocardiogram abnormalities at screening.
efficacy and safety study for an oral contraceptive containing folate

Conditions: Neural Tube Defects; Contraception; Oral Contraceptives (OC)

Summary: the purpose of this study is to determine whether the study drug is safe and effective

acronym is used in result section: suspected/diagnosed (susp/diag)

Eligibility criteria:
inclusion criteria: - healthy women between 18 and 40 requesting oral contraception exclusion criteria: - the use of steroidal oral contraceptives, or any drug that could alter oral contraception metabolism will be prohibited during the study

Keywords: healthy women requesting contraception folic acid
prevalence of may-thurner syndrome in 1st-degree relatives of symptomatic patients

Conditions: May-Thurner Syndrome

Summary: the aim is to assess the prevalence of may-thurner syndrome in 1st-degree relatives of previously identified symptomatic patients.

may-thurner syndrome (mts) is a condition characterised by compression of the left common iliac vein by the right common iliac artery and the anterior spine of the 5th lumbar vertebrae. previously thought to be a rare condition, the prevalence of mts is thought to be underreported. mts can lead to significant morbidity in the form of chronic venous insufficiency, venous ulceration, lower limb swelling, venous claudication, deep-vein thrombosis, varicose veins, pelvic congestion syndrome, chronic pelvic pain and chronic post-thrombotic syndrome. it is a known risk factor for development of venous incompetence and varicose veins in adolescents and young adults. furthermore, it is known to be an a causative factor in the development of "unprovoked" dvt in younger patients, however data on the risk of development of dvt in mts patients has to date, been unavailable. the pathogenesis of mts is largely unknown and whilst the condition is known to be more prevalent in females, familial risk factors are largely unknown. to date, no studies have previously assessed the prevalence of mts in relatives of those with the condition.

Eligibility criteria:
inclusion criteria: * informed consent, first degree relative with symptomatic may-thurner syndrome exclusion criteria: * those who not give informed consent to be contacted or to be scanned.
intraprostatic prx302 injection to treat localised prostate cancer

Conditions: Prostate Cancer

Summary: the purpose of this study is to determine a safe, effective, and tolerable dose of prx302 for the treatment of low to intermediate risk prostate cancer.

a multi-centre, open label, phase iib study, evaluating the safety, tolerability and efficacy of a targeted intraprostatic focal administration in development. the study will treat approximately 40 men who meet the eligibility criteria, and give written consent. safety and tolerability will be assessed post-treatment over 26 weeks. efficacy will be assessed by biopsy and imaging (mpmri) at 24 weeks.

Eligibility criteria:
inclusion criteria: * life expectancy ≥ 10 years. * serum prostate-specific antigen (psa) ≤ 15ng/ml. * a histologically proven, clinically significant lesion visible on mpmri (magnetic resonance imaging) that is accessible to prx302 transperineal injection. * radiological stage t1-t2 n0 mx/m0 disease. * targeted prostate biopsy within 6 months prior to dosing, with a clinically significant lesion correlating with an mpmri visible lesion. exclusion criteria: * previous radiation therapy to the pelvis. * androgen suppression or anti-androgen therapy within the 12 months prior to dosing, for prostate cancer. * use of 5-alpha reductase inhibitor within the 3 months prior to dosing. * evidence of metastatic disease or nodal disease outside the prostate on bone scan or cross-sectional imaging. * inability to tolerate transrectal ultrasound (trus). * known allergy to latex or gadolinium (gd). * prior rectal surgery preventing insertion of the trus probe. * any previous ablative procedures performed on the prostate, e.g., electroporation, radiofrequency ablation, high-intensity focused ultrasound (hifu), cryosurgery, photochemical, thermal or microwave therapy to treat cancer of the prostate. * unable to have pelvic mri scanning (severe claustrophobia, permanent cardiac pacemaker, metallic implant, etc., likely to contribute significant artifact to images).

Keywords: intraprostatic mri lesion prostate biopsies
study to compare initial dosing parameters of zemplar in stage v chronic kidney disease subjects on hemodialysis

Conditions: Kidney Failure, Chronic

Summary: to show non-inferiority in the incidence rates of elevated calcium-phosphorus product between two treatment groups: 1) a group having an initial dose based on baseline pth (baseline ipth/80) and 2) a group having a starting dose based on body weight (0.04 mcg/kg).


Eligibility criteria:
inclusion criteria: * stage v chronic kidney disease * patients on hemodialysis requiring treatment for secondary hyperparathyroidism with vitamin d therapy

Keywords: stage v chronic kidney disease
n-terminal pro-b-type natriuretic peptide and troponin levels as markers of hemodynamic stability in very low birth weight infants during the first days of life

Conditions: Hypotension; Very Low Birth Weight Infants; Ventricular Dysfunction; Prematurity

Summary: the primary objective is to test the hypothesis that there is an association between the hemodynamic status and the serum levels of nt-probnp and ctnt in prematurely born infants. we would also evaluate the hypothesis that there is an association between the level of these proteins in the serum and the short and long term morbidity.

nt-probnp is a member of the natriuretic hormone family which plays an important role in regulation of extracellular fluid volume and blood pressure.it is secreted from the cardiac ventricle myocytes in response to myocardial stress. this hormone serves as a marker of ventricular dysfunction in adults but its role in newborns and especially preterm infants has not been well studied yet. following birth of a healthy infant there is a surge in nt-probnp levels which is then followed by a rapid decrease. one explanation for this surge is the transition in hemodynamics from fetal circulation into postnatal one. few studies conducted in this area have shown association between nt-probnp level and patency of ductus arteriosus and with respiratory distress syndrome of the newborn. cardiac troponin t (ctnt)is a specific cardiac protein which serves as a specific indicator of cardiac damage in adults, it is usually not detected at birth but following myocardial injury its serum levels will slowly rise and generally will not be detectable until at least 4 hours after onset of injury. there is no "gold standard" test for diagnosis of hemodynamic instability in very low birth weight infants. myocardial dysfunction is thought to be the major cause for this condition in vlbw population. since this condition is associated with severe short and long term morbidity early recognition and specific treatment may be detrimental. we hypothesized that nt-probnp and ctnt levels may serve as a more accurate markers for diagnosis, monitoring, and outcome prediction in vlbw infants during the first days of life, than the methods we currently use (blood pressure, urine output etc.)

Eligibility criteria:
inclusion criteria: * vlbw infants born at sheba medical center exclusion criteria: * known cardiac or chromosomal anomaly

Keywords: n-terminal pro-bnp, cardiac troponin-t, very low birth weight infants hemodynamic instability myocardial dysfunction
medical complications in familial and multifactorial chylomicronaemia syndromes

Conditions: Familial Chylomicronemia Syndrome; Multifactorial Chylomicronemia Syndrome

Summary: a retrospective, systematic study of reimbursed healthcare costs over a 10 year period in patients suffering from familial chylomicronaemia syndromes (fcs) or multifactorial chylomicronaemia syndromes (mcs) in order to establish the relative healthcare burden of both syndromes by linking the hospices civils de lyon (hcl) registry of fcs or mcs patients and data obtained from fcs or mcs patients followed in paris, nantes and lyon to the french national health system (nhs) healthcare claims database, the système national d'information inter-régimes de l'assurance maladie (sniir-am). a probabilistic approach will be used to link databases. this linkage will be based on the following variables: age, gender, date of discharge of any hospitalization, date of any imaging procedure. this study will help to describe, in real life, the management of severe hyperglyceridaemia in france. in addition, the descriptive results will help obtain a better understanding of the patients suffering from this disease, the burden of the disease and the healthcare consumption linked to this disease. even if this consumption of care has been relatively unexplored until this point, it is not negligible. the potential of merging genomics and claims data for cardiovascular research could help to identify ways to optimize disease


Eligibility criteria:
inclusion criteria: * genetically documented fcs * genetically documented mcs exclusion criteria: * none
photobiomodulation for the management of temporomandibular disorder pain

Conditions: Pain Related to TMD

Summary: photobiomodulation (pbm), is fda-approved for temporary relief of muscle and joint pain, but there is no indication for tmd. our goal in this study is to conduct a clinical trial of multimodal pbm for tmd pain. also, we propose to determine if pbm-induced changes in inflammation contribute to pbm's analgesic effects. this study will be a double-blind, sham-controlled, randomized trial testing the efficacy of pbm for pain related to tmd.


Eligibility criteria:
inclusion criteria: * provides a signed and dated informed consent form * is at least 18 years of age (male or female and any race or ethnicity) * meets diagnostic criteria for tmd, ( masticatory muscle disorders, 1a: myalgia) * has experienced facial pain for at least 3 months * at screening and baseline visit (visit 0), reports an average pain intensity rating over the past week of ≥ 30 on a numerical rating scale (0-100) exclusion criteria: * starting a new daily prescription medication for the management of pain within 30 days prior to treatment session; * use of any injection therapy (e.g., tender or trigger point injections, steroid injections) for the management of pain within 2 weeks prior to the cati; * starting occlusal appliance therapy within 30 days prior to cati; d) history of facial trauma or orofacial surgery within 6 weeks prior to cati; * active orthodontic treatment; * psychiatric hospitalization within one year prior to screening. * has known hypersensitivity to laser therapy. * currently being treated with chemotherapy or radiation therapy * has been treated with another investigational drug or treatment within 30 days prior to the screening and baseline visit * is pregnant or nursing * anything that, in the opinion of the investigator, would place the participant at increased risk or preclude the participant's full compliance with or completion of the study